NEWS HIGHLIGHTS
Published Studies Related to Cosopt (Dorzolamide / Timolol Ophthalmic)
Additive Intraocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% (Cosopt) on Monotherapy With Latanoprost (Xalatan) in Patients With Elevated Intraocular Pressure: A Prospective, 4-week, Open-label, Randomized, Controlled Clinical Trial. [2009.09.02]
PURPOSE: To evaluate the additive effect of dorzolamide/timolol fixed combination in patients under monotherapy with latanoprost... CONCLUSIONS: In our sample, dorzolamide 2%/timolol 0.5% fixed combination as add-on therapy in patients with open-angle glaucoma or ocular hypertension under monotherapy with latanoprost with IOP already in mid-teens levels may further enhance pressure reduction.
Dorzolamide-timolol combination and retinal vessel oxygen saturation in patients with glaucoma or ocular hypertension. [2009.08]
AIMS: To examine whether the addition of dorzolamide to timolol monotherapy influences oxygen saturation in the human retina... CONCLUSION: Adding dorzolamide to timolol monotherapy has a minimal effect, but going from dorzolamide-timolol combination to timolol alone lowered arteriolar and venular oxygen saturation. The retinal oxygen saturation measurements show a high degree of stability over an extended period of time. Previous studies have suggested increased retinal and optic nerve blood flow with dorzolamide. Unchanged oxygen saturation and increased blood flow would indicate increased oxygen delivery to the retina.
An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. [2008.12]
PURPOSE: To compare the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure (IOP) over 8 weeks... CONCLUSIONS: Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment. Also, both fixed combinations are well tolerated with few side effects.
Dorzolamide/Timolol fixed combination versus latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. [2008.02]
Purpose: The efficacy of dorzolamide/timolol fixed combination (DTFC) versus latanoprost/timolol fixed combination (LTFC) in open-angle glaucoma or ocular hypertensive patients. Methods: Patients were randomized to DTFC or LTFC for 6 weeks and switched to opposite treatment for Period 2... Conclusions: Patients treated with DTFC and LTFC have a statistically similar ocular hypotensive effect.
Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. [2008.01]
PURPOSE: To evaluate the 24-hour intraocular pressure (IOP)-lowering effect of latanoprost and the dorzolamide/timolol fixed combination (DTFC) after 2 and 6 months of treatment. DESIGN: Randomized, prospective, crossover comparison. PARTICIPANTS: Thirty-nine patients had primary open-angle glaucoma, and 14 patients had ocular hypertension... CONCLUSIONS: After 6 months of therapy, the DTFC and latanoprost have clinically similar 24-hour IOP-lowering efficacies.
Clinical Trials Related to Cosopt (Dorzolamide / Timolol Ophthalmic)
Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure [Not yet recruiting]
Hypothesis: Studies suggest that patients with low diastolic velocity and high resistivity
index in the ophthalmic artery had more progressive visual fields, the investigators
hypothesize therefore that addition of Cosopt to Latanoprost could improve ocular
diastolic perfusion pressure (ODPP).
Objective: To evaluate the effects of Cosopt on ODPP in patients not adequately controlled
with latanoprost alone.
12-Month Stability of Diurnal IOP Control on Cosopt [Active, not recruiting]
To determine the stability of diurnal intraocular pressure in eyes with glaucoma treated with
Cosopt
The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-Angle Glaucoma (POAG) [Recruiting]
Both Cosopt® and Xalatan® plus Timoptic® will significantly lower IOP, however only Cosopt®
will demonstrate positive hemodynamic effects. The clinical significance of this will be
investigated by examining the ophthalmic and short posterior ciliary arteries to determine
the blood supply to the optic nerve head, the site of damage in glaucoma
Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma. [Recruiting]
WHAT IS THIS STUDY ABOUT? Glaucoma and ocular hypertension are chronic eye diseases that can
damage the optic nerve and lead to vision loss or blindness. The optic nerve acts like an
electric cable with over a million wires. This nerve is responsible for carrying images
from the eye to the brain. The way glaucoma and ocular hypertension cause blindness depends
on many factors, but the most important factor is the increased pressure inside the eye
(intraocular pressure).
There is no cure for glaucoma or ocular hypertension. However, lowering the pressure inside
the eye has been shown to slow the progression of disease. Intraocular pressure can be
lowered by glaucoma medication, laser treatment, or surgery.
You have open angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension.
Researchers want to find out more about how 2 drugs called Cosopt (dorzolamide hydrochloride
and timolol maleate) and Xalatan (latanoprost) can help people with these conditions.
Cosopt and Xalatan are both eye drops that are approved by the U. S. Food and Drug
Administration (FDA) to reduce intraocular pressure in people with open angle glaucoma and
ocular hypertension.
The study doctor will do a laser procedure called Selective Laser Trabeculoplasty (SLT) on
people in this study to help lower their intraocular pressure. The FDA has approved SLT to
treat open angle glaucoma and ocular hypertension.
Then the study doctor will ask some participants to use either Cosopt or Xalatan, if their
intraocular pressure is still too high 4 to 6 weeks after the SLT procedure. The study
doctor wants to see which of the 2 study drugs (Cosopt or Xalatan) is better at reducing
intraocular pressure after SLT.
It is planned that about 30 people with glaucoma or ocular hypertension who are at least 18
years old will be in this study. Out of the participants whose intraocular pressure is
still too high after SLT, half will use Cosopt and half will use Xalatan. You do not have
to be in this study to have SLT or to use Cosopt or Xalatan.
A Investigator Masked Parallel Comparison of Tolerability of Combigan and Cosopt [Recruiting]
|
